TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta, Biologics, Antibody, Claudin 18.2

TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Careers Contact
Scientific Publications

A Phase I Study of TST001, a Humanized Anti-CLDN18.2 Monoclonal Antibody, in Combination with Capecitabine and Oxaliplatin (CAPOX) as a First Line Treatment of Advanced G/GEJ Cancer

13 Sep, 2022


Jifang Gong1 , Ning Li2 , Weijian Guo3, Tianshu Liu4 , Hongli Li5 , Jiayi Li 6 , Zhenzhong Xia7 , Chunhua Qian 7 , Jenny Yao 8 , Jianming Wang 8 , Lijuan Zhang 7 , Chuan Qi 7 , Michael Shi 8 , Xu,Li 8 , Caroline Germa 8 , Xueming Qian 7 , Lin Shen 1 ;

1Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; 

2Henan Cancer Hospital, Zhengzhou, China; 

3Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; 

4Zhongshan Hospital, Fudan University, Shanghai, China; 

5Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; 

6The First Affiliated Hospital of Xiamen University, Xiamen, China; 

7Suzhou Transcenta Therapeutics Co., Ltd; 

8Transcenta Therapeutics Inc.


TST001 is a recombinant humanized antibody that can specifically bind to the  extracellular structure of Claudin18.2 (CLDN18.2) protein and eliminate cancer cells  by antibody-dependent cellular cytotoxicity and complement-dependent  cytotoxicity.  

Pre-clinical studies have shown that TST001 has synergistic effect when used in  combination with chemotherapy.


TST001 in combination with CAPOX as the first line treatment of patients with G/GEJ  cancer is well tolerated and encouraging anti-tumor activities have been observed.  CLDN18.2 expression thresholds and correlation with efficacy are being further  assessed.

1 个附件